دورية أكاديمية
Iron chelators as a therapeutic option for Alzheimer's disease-A mini-review.
| العنوان: | Iron chelators as a therapeutic option for Alzheimer's disease-A mini-review. |
|---|---|
| المؤلفون: | Schreiner OD; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.; Medical Oncology Department, Regional Institute of Oncology, Iasi, Romania., Schreiner TG; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.; Faculty of Electrical Engineering and Information Technology, Gheorghe Asachi Technical University of Iasi, Iasi, Romania.; Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania. |
| المصدر: | Frontiers in aging [Front Aging] 2023 Aug 02; Vol. 4, pp. 1234958. Date of Electronic Publication: 2023 Aug 02 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 9918231199706676 Publication Model: eCollection Cited Medium: Internet ISSN: 2673-6217 (Electronic) Linking ISSN: 26736217 NLM ISO Abbreviation: Front Aging Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne, Switzerland : Frontiers Research Foundation, [2020]- |
| مستخلص: | Neurodegenerative disorders, particularly Alzheimer's disease (AD), remain a great challenge regarding the finding of effective treatment, one main reason being the incomplete understanding of their etiology. With many intensely debated hypotheses, a newer approach based on the impact of iron imbalance in sustaining neurodegeneration in the central nervous system becomes increasingly popular. Altered iron homeostasis leads to increased iron accumulation in specific brain areas, explaining the clinical picture of AD patients. Moreover, growing evidence sustains the significant impact of iron metabolism in relationship to other pathological processes encountered in the AD-affected brain, such as the amyloidogenic pathway, chronic inflammation, or oxidative stress. In this context, this mini-review aims to summarize the novel data from the continuously expanding literature on this topic in a didactic manner. Thus, in the first part, the authors briefly highlight the most relevant aspects related to iron absorption, transport, regulation, and elimination at the cerebral level, focusing on the role of the blood-brain barrier and the newer concept of ferroptosis. Subsequently, currently available iron chelation therapies are discussed, including an overview of the most relevant clinical trials on this topic. In the final part, based on the latest results from in vitro and in vivo studies, new research directions are suggested to enhance the development of effective antidementia therapies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Schreiner and Schreiner.) |
| References: | Chem Rev. 2014 Apr 9;114(7):3919-62. (PMID: 24400737) Int J Neuropsychopharmacol. 2023 Jan 19;26(1):1-8. (PMID: 35986919) Front Neurosci. 2019 Jan 08;12:988. (PMID: 30670944) J Am Heart Assoc. 2022 Mar 15;11(6):e024648. (PMID: 35229619) Int J Mol Sci. 2021 Nov 18;22(22):. (PMID: 34830326) Neural Plast. 2021 Dec 6;2021:6564585. (PMID: 34912450) Front Pharmacol. 2020 Mar 17;11:239. (PMID: 32256352) Eur J Pharmacol. 2020 Nov 15;887:173554. (PMID: 32941929) Stem Cells. 2019 Oct;37(10):1293-1306. (PMID: 31381839) Int J Mol Sci. 2023 Feb 11;24(4):. (PMID: 36835065) Pharmaceuticals (Basel). 2018 Dec 14;11(4):. (PMID: 30558109) Front Hum Neurosci. 2022 Jul 13;16:838692. (PMID: 35911597) Acta Neuropathol Commun. 2021 Feb 17;9(1):27. (PMID: 33597025) Int J Mol Sci. 2022 Jun 30;23(13):. (PMID: 35806270) IUBMB Life. 2011 Feb;63(2):120-8. (PMID: 21360641) Front Neurol. 2019 Jun 19;10:607. (PMID: 31275224) Front Neurosci. 2021 Aug 19;15:688090. (PMID: 34489623) Front Med (Lausanne). 2023 Feb 15;10:1015711. (PMID: 36873870) Metallomics. 2017 Nov 15;9(11):1655-1665. (PMID: 29072765) Ageing Res Rev. 2017 May;35:265-290. (PMID: 27829171) Biochim Biophys Acta. 2012 Mar;1820(3):188-202. (PMID: 22085723) J Pediatr Hematol Oncol. 2006 Jan;28(1):11-6. (PMID: 16394886) Cell. 2023 Feb 16;186(4):693-714. (PMID: 36803602) Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188706. (PMID: 35247507) Sci Rep. 2020 Feb 20;10(1):3061. (PMID: 32080266) Adv Drug Deliv Rev. 2020;165-166:1-14. (PMID: 31790711) Front Oncol. 2021 May 19;11:638856. (PMID: 34094919) Front Immunol. 2018 Oct 15;9:2296. (PMID: 30374347) Free Radic Biol Med. 2019 Mar;133:3-10. (PMID: 30236787) Antioxidants (Basel). 2022 Mar 31;11(4):. (PMID: 35453377) Front Neurol. 2021 Aug 31;12:619626. (PMID: 34531807) Neuroimage. 2019 May 1;191:176-185. (PMID: 30739060) Front Mol Biosci. 2022 Aug 26;9:965064. (PMID: 36090039) Int J Mol Sci. 2021 Jun 17;22(12):. (PMID: 34204327) J Int Adv Otol. 2017 Apr;13(1):136-139. (PMID: 27879229) Int J Mol Sci. 2022 Oct 25;23(21):. (PMID: 36361631) Mol Neurodegener. 2022 Nov 8;17(1):72. (PMID: 36348357) Neurosci Biobehav Rev. 2016 Sep;68:727-740. (PMID: 27422450) Front Neurol. 2019 Jun 07;10:594. (PMID: 31231305) Neurobiol Dis. 2015 Sep;81:49-65. (PMID: 26303889) Eur J Haematol. 2023 May;110(5):490-497. (PMID: 36708354) Pharmaceuticals (Basel). 2018 Nov 23;11(4):. (PMID: 30477086) Free Radic Biol Med. 2001 Jan 15;30(2):170-7. (PMID: 11163534) Front Immunol. 2022 Apr 26;13:856376. (PMID: 35558075) Int J Mol Sci. 2022 Sep 02;23(17):. (PMID: 36077413) Transl Gastroenterol Hepatol. 2020 Apr 05;5:25. (PMID: 32258529) Sci Rep. 2022 Oct 21;12(1):17708. (PMID: 36271285) Br J Pharmacol. 2019 Sep;176(18):3622-3635. (PMID: 30632143) Front Mol Neurosci. 2015 Jun 03;8:18. (PMID: 26089776) Mol Psychiatry. 2017 Mar;22(3):328-335. (PMID: 27777421) Eur J Haematol. 2016 Mar;96(3):318-26. (PMID: 26018112) Alzheimers Dement. 2023 Feb;19(2):658-670. (PMID: 35652476) Drug Discov Today. 2021 Mar;26(3):794-803. (PMID: 33306995) Int J Mol Sci. 2020 Oct 16;21(20):. (PMID: 33081348) Brain Res. 2021 Feb 1;1752:147234. (PMID: 33412145) Mol Biol Cell. 2021 Jan 15;32(2):98-108. (PMID: 33236955) Fluids Barriers CNS. 2022 Jun 10;19(1):49. (PMID: 35689283) Nutrients. 2015 Mar 31;7(4):2274-96. (PMID: 25835049) Crit Rev Food Sci Nutr. 2019;59(3):443-449. (PMID: 28886251) Mol Med. 2018 Mar 15;24(1):5. (PMID: 30134796) PLoS One. 2020 Oct 15;15(10):e0240697. (PMID: 33057378) Hum Brain Mapp. 2023 Jun 1;44(8):3072-3083. (PMID: 36929676) Neuroepidemiology. 2022;56(5):309-318. (PMID: 35728570) Front Mol Neurosci. 2018 Jan 19;10:455. (PMID: 29403352) Medicines (Basel). 2020 Jul 30;7(8):. (PMID: 32751493) Expert Rev Mol Med. 2007 Dec 05;9(33):1-13. (PMID: 18053288) Brain. 2020 May 1;143(5):1341-1349. (PMID: 32330946) Lancet. 1991 Jun 1;337(8753):1304-8. (PMID: 1674295) Am J Physiol Gastrointest Liver Physiol. 2014 Aug 15;307(4):G397-409. (PMID: 24994858) Front Immunol. 2020 May 28;11:1221. (PMID: 32574271) Cell Death Dis. 2022 Jan 10;13(1):40. (PMID: 35013137) J Neurochem. 2022 Jan;160(1):64-73. (PMID: 33733478) Cell Transplant. 2019 Aug;28(8):1009-1017. (PMID: 30776900) J Res Med Sci. 2014 Feb;19(2):164-74. (PMID: 24778671) J Toxicol. 2022 May 5;2022:4911205. (PMID: 35571382) Front Aging Neurosci. 2020 Dec 21;12:603854. (PMID: 33424580) Nat Rev Drug Discov. 2022 Apr;21(4):306-318. (PMID: 35177833) Neuroimage. 2021 Oct 1;239:118267. (PMID: 34139358) Sci Rep. 2022 Jul 9;12(1):11724. (PMID: 35810203) Nutrients. 2022 Aug 24;14(17):. (PMID: 36079734) Am J Respir Cell Mol Biol. 2021 Aug;65(2):189-200. (PMID: 33861690) Front Immunol. 2022 Jan 06;12:796867. (PMID: 35069578) Eur J Pharmacol. 2020 Nov 5;886:173513. (PMID: 32898550) Biomedicines. 2021 Oct 30;9(11):. (PMID: 34829813) Biomolecules. 2022 Feb 25;12(3):. (PMID: 35327557) J Clin Med. 2022 Apr 03;11(7):. (PMID: 35407617) J Trace Elem Med Biol. 2012 Jun;26(2-3):115-9. (PMID: 22575541) Pharmaceuticals (Basel). 2018 Oct 19;11(4):. (PMID: 30347635) Mol Psychiatry. 2020 Nov;25(11):2932-2941. (PMID: 30778133) Front Aging Neurosci. 2022 Mar 22;14:830569. (PMID: 35391749) Medicines (Basel). 2019 Aug 05;6(3):. (PMID: 31387234) Cell. 2012 May 25;149(5):1060-72. (PMID: 22632970) Antioxidants (Basel). 2021 Nov 24;10(12):. (PMID: 34942967) Front Neurosci. 2018 Sep 10;12:632. (PMID: 30250423) Cochrane Database Syst Rev. 2018 Jul 12;7:CD011626. (PMID: 29998494) Front Aging Neurosci. 2022 Jun 30;14:888989. (PMID: 35847685) Front Pharmacol. 2014 Jun 13;5:124. (PMID: 24982634) |
| فهرسة مساهمة: | Keywords: Alzheimer’s disease; aging; ferroptosis; iron homeostasis; metabolism and redox biology chelation; neurodegenearation |
| تواريخ الأحداث: | Date Created: 20230821 Latest Revision: 20240215 |
| رمز التحديث: | 20240215 |
| مُعرف محوري في PubMed: | PMC10433644 |
| DOI: | 10.3389/fragi.2023.1234958 |
| PMID: | 37602277 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!